Abstract
We describe the use of a parametric lognormal model to calculate and compare survival statistics in the clinical treatment of advanced/metastatic pancreatic, breast and colon cancers. The fit using the lognormal model explained greater than 90% (R2 ranged from 0.917 to 0.998 for a total of the 51 arms from published studies) of the variation in the cumulative survival statistics of patients treated for advanced cancers. A meta-analytic Q-test was performed to test whether there were significant differences between different studies. For all three cancer types, the Q-test showed highly significant differences between the survival arms (p < 0.0001 for pancreatic, breast and colon cancers). The z-values expressed the difference of the average of lognormal means relative to each study in terms of deviation expressed in standard errors. The treatments that were most effective ranked with the highest z-value: Doxorubicin plus docetaxel for pancreatic cancer (z-value = 4.1); Capecitabine plus paclitaxel for breast cancer (z-value = 3); irinotecan, fluorouracil and folinate for colon cancer (z-value = 7.4).
Keywords: kaplan-meier (km) method, cancer-specific survival rates (cssr), lognormal model, tumor growth, bay, cetuximab, colon cancer
Current Pharmaceutical Design
Title: Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols
Volume: 13 Issue: 15
Author(s): S. Qazi, D. DuMez and F. M. Uckun
Affiliation:
Keywords: kaplan-meier (km) method, cancer-specific survival rates (cssr), lognormal model, tumor growth, bay, cetuximab, colon cancer
Abstract: We describe the use of a parametric lognormal model to calculate and compare survival statistics in the clinical treatment of advanced/metastatic pancreatic, breast and colon cancers. The fit using the lognormal model explained greater than 90% (R2 ranged from 0.917 to 0.998 for a total of the 51 arms from published studies) of the variation in the cumulative survival statistics of patients treated for advanced cancers. A meta-analytic Q-test was performed to test whether there were significant differences between different studies. For all three cancer types, the Q-test showed highly significant differences between the survival arms (p < 0.0001 for pancreatic, breast and colon cancers). The z-values expressed the difference of the average of lognormal means relative to each study in terms of deviation expressed in standard errors. The treatments that were most effective ranked with the highest z-value: Doxorubicin plus docetaxel for pancreatic cancer (z-value = 4.1); Capecitabine plus paclitaxel for breast cancer (z-value = 3); irinotecan, fluorouracil and folinate for colon cancer (z-value = 7.4).
Export Options
About this article
Cite this article as:
Qazi S., DuMez D. and Uckun M. F., Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols, Current Pharmaceutical Design 2007; 13 (15) . https://dx.doi.org/10.2174/138161207780765882
DOI https://dx.doi.org/10.2174/138161207780765882 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis, Spectroscopic Properties, Crystal Structure And Biological Evaluation of New Platinum Complexes with 5-methyl-5-(2-thiomethyl)ethyl Hydantoin
Anti-Cancer Agents in Medicinal Chemistry Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry Therapeutic Monoclonal Antibodies: Strategies and Challenges for Biosimilars Development
Current Medicinal Chemistry Purinergic Receptors and Pain
Current Pharmaceutical Design MicroRNAs in the Pathobiology of Multiple Myeloma
Current Cancer Drug Targets Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Recent Patents on Anti-Cancer Drug Discovery Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Isatin Hybrids and Their Pharmacological Investigations
Mini-Reviews in Medicinal Chemistry MUC1 Story: Great Expectations, Disappointments and the Renaissance
Current Medicinal Chemistry NEDD4: A Promising Target for Cancer Therapy
Current Cancer Drug Targets White Poplar (Populus alba L.) Suspension Cultures as a Model System to Study Apoptosis Induced by Alfalfa Saponins
Anti-Cancer Agents in Medicinal Chemistry The Impact of In Vitro Fertilization on the Health of the Mother and the Offspring
Current Women`s Health Reviews Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Progression
Current Cancer Drug Targets Structure-Activity Relationship Studies on ADAM Protein-Integrin Interactions
Cardiovascular & Hematological Agents in Medicinal Chemistry Role of FoxM1 in the Progression and Epithelial to Mesenchymal Transition of Gastrointestinal Cancer
Recent Patents on Anti-Cancer Drug Discovery Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Oncogenic LncRNA CASC9 in Cancer Progression
Current Pharmaceutical Design Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology Breast Cancer Diagnosis System Based on the Fusion of Local Binary and Ternary Patterns from Ultrasound B Mode and Elastography Images
Current Medical Imaging Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology